Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients

被引:27
|
作者
Bozza, Claudia [1 ]
Puglisi, Fabio [1 ,2 ]
Lambertini, Matteo [3 ]
Osa, Etin-Osa [4 ]
Manno, Massimo [5 ]
Del Mastro, Lucia [6 ]
机构
[1] Univ Hosp Udine, Dept Oncol, Udine, Italy
[2] Univ Udine, Dept Med & Biol Sci, I-33100 Udine, Italy
[3] IRCCS AOU San Martino IST, Dept Med Oncol UO Oncol Med A, I-16132 Genoa, Italy
[4] NYU, Sch Med, Dept Radiat Oncol, New York, NY USA
[5] Pordenone Hosp, Mother & Child Dept, Pordenone, Italy
[6] IRCCS AOU San Martino IST, Dept Med Oncol SS Sviluppo Terapie Innovat, Genoa, Italy
关键词
breast; growth factor; hormone action; oncology; SERUM ANTIMULLERIAN HORMONE; INHIBITING SUBSTANCE LEVELS; IN-VITRO FERTILIZATION; FERTILITY PRESERVATION; PREMENOPAUSAL WOMEN; YOUNG-WOMEN; CHILDHOOD-CANCER; FOLLICLE RECRUITMENT; TECHNOLOGY CYCLES; AMERICAN-SOCIETY;
D O I
10.1530/ERC-13-0335
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer is the most common invasive cancer in women of reproductive age. In young women, chemotherapy may induce amenorrhea: it is still uncertain how to assess menopausal status in these patients despite the importance of its definition for choosing appropriate endocrine treatment. In the development of sensitive biomarkers for fertility and ovarian reserve, anti-Mullerian hormone (AMH) is considered a promising marker of ovarian reserve. The clearest data regarding a clinical use of AMH are related to the measurement of the ovarian pool in women who undergo IVF: the available data, also in breast cancer patients, seem to suggest that AMH measurement, before gonadotropin administration, can be a useful marker for the prediction of women at risk for poor-response or no response to ovarian stimulation. The utility of AMH as a potential marker of chemotherapy-induced ovarian follicular depletion and an early plasma marker of chemotherapy-induced gonadal damage has been evaluated both in young women after treatment for cancer in childhood and in young survivors of hematological malignancies and solid tumors. Several studies have demonstrated a potential utility of AMH, inhibin, or follicle-stimulating factor as biomarkers predicting infertility risk in breast cancer patients, but the studies conducted so far are not conclusive. Further studies are needed in order to define the regimen-specific action of chemotherapy on AMH levels, the percentage of post-treatment recovery of plasma levels of the hormone, and the relationship between menopausal status and AMH.
引用
收藏
页码:R51 / R65
页数:15
相关论文
共 50 条
  • [21] Association of Myomectomy with Anti-Mullerian Hormone Levels and Ovarian Reserve
    Liang, Xuzhi
    Fan, Jiangtao
    OBSTETRICS AND GYNECOLOGY, 2023, 141 (03): : 624 - 624
  • [22] Anti-Mullerian hormone, an ovarian reserve marker in hypogonadotropic hypogonadism
    Oncul, Mahmut
    Ozcivit, Ipek Betul
    Basibuyuk, Zafer
    Cebi, Ceren
    Sahmay, Sezai
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2022, 273 : 54 - 58
  • [23] The roles of anti-Mullerian hormone in breast cancer
    Chen, Xuan
    Liu, Sixuan
    Peng, Xue
    Zong, Xiangyun
    ENDOCRINE-RELATED CANCER, 2023, 30 (10)
  • [24] Anti-mullerian hormone as a marker of ovarian reserve after laparoscopic ovarian cystectomy
    Iwase, A.
    Hirokawa, W.
    Goto, M.
    Nagatomo, Y.
    Bayasula, B.
    Kobayashi, H.
    Kobayashi, H.
    Nakahara, T.
    Takikawa, S.
    Manabe, S.
    Kikkawa, F.
    HUMAN REPRODUCTION, 2010, 25 : I64 - I64
  • [25] Serum anti-Mullerian hormone as a marker of ovarian reserve among childhood cancer survivors
    Molinari, Silvia
    Parissone, Francesca
    Evasi, Veronica
    Di Marco, Santo
    Biondi, Andrea
    Cattoni, Alessandro
    HORMONE RESEARCH IN PAEDIATRICS, 2021, 94 (SUPPL 1): : 147 - 147
  • [26] Assessment of ovarian reserve: Anti-Mullerian hormone versus follicle stimulating hormone
    Jamil, Zehra
    Fatima, Syeda Sadia
    Cheema, Zahra
    Baig, Safia
    Choudhary, Roha Ahmed
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2016, 21
  • [27] Assessment of ovarian reserve in adult childhood cancer survivors using anti-Mullerian hormone
    Fong, S. Lie
    Laven, J. S. E.
    Hakvoort-Cammel, F. G. A. J.
    Schipper, I.
    Visser, J. A.
    Themmen, A. P. N.
    de Jong, F. H.
    van den Heuvel-Eibrink, M. M.
    HUMAN REPRODUCTION, 2009, 24 (04) : 982 - 990
  • [28] ASSESSMENT OF OVARIAN RESERVE WITH ANTI-MULLERIAN HORMONE IN FEMALE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
    Zhan, Z.
    Chen, D.
    Yuan, S.
    Liang, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 601 - 601
  • [29] Is Anti-Mullerian Hormone Associated with IVF Outcomes in Young Patients with Diminished Ovarian Reserve?
    Pereira, Nigel
    Setton, Robert
    Petrini, Allison C.
    Lekovich, Jovana P.
    Elias, Rony T.
    Spandorfer, Steven D.
    WOMENS HEALTH, 2016, 12 (02) : 185 - 192
  • [30] Serum Anti-Mullerian Hormone Levels in Patients with Epithelial Ovarian Cancer
    Walentowicz, Pawel
    Sadlecki, Pawel
    Krintus, Magdalena
    Sypniewska, Grazyna
    Mankowska-Cyl, Aneta
    Grabiec, Marek
    Walentowicz-Sadlecka, Malgorzata
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2013, 2013